Sangamo Biosciences, Inc.

Sangamo Therapeutics, Inc.

Dow Agrosciences LLC

University of Texas System

University of California

Children's Medical Center Corporation

Sigma-aldrich Co. LLC

Corteva Agriscience LLC

Whitehead Institute for Biomedical Research

Fyodor Urnov

Philip D Gregory

Michael C Holmes

Jeffrey C Miller

David Paschon

Edward J Rebar

Lei Zhang

Gregory J Cost

Andreas Reik

Dmitry Y Guschin

Trevor Collingwood

Russell DeKelver

Siyuan Tan

Alan P Wolffe

Vipula Shukla

Manju Gupta

Jianbin Wang

Anthony Conway

Casey Christopher Case

Phillip Tam

Sarah E Worden

H Steve Zhang

Joseph F Petolino

Lakshmi Sastry-Dent

Elizabeth J Wolffe, Legal Representative

Xiangdong Meng

Andrew Snowden

Matthew C Mendel

Stephen N Novak

Laurence J N Cooper

Nicole Arnold

Paul Bundock

Ryan C Blue

Jon Christopher Mitchell

Qihua C Cai

Robbi J Garrison

Michael Moore

Carl O Pabo

Dmitry M Guschin

Asha Mehra Palta

Xiao-Yong Li

Brian Johnstone

Timothy Farries

Albert Lai

Sunita Gopalan

Lisa W Baker

Michiel Jan De Both

Noriyuki Kasahara

Yannick Doyon

Josee Laganiere

David Richard Corbin

Steven Robert Webb

Rudolf Jaenisch

Holly Jean Butler

Jayakumar Pon Samuel

W Michael Ainley

William M Ainley

Stuart H Orkin

Michael G Murray

Bryan Zeitler

Aron M Geurts

Frank Soldner

Elizabeth J Wolffe

Zhifang Gao

Xiaoxia Cui

Shuyuan Yao

Dirk Hockemeyer

Russell DeKeiver

Eva Raschke

Elizabeth Wolffe

Asha M Palta

Jeffrey Miller

Vipula K Shukla

Nicole L Arnold

Rudolf Jaenish

Russell Dekelver

Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.

DNA-binding proteins and uses thereof

Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.

Targeted integration into the PPP1R12C locus

Methods and compositions for a genetic disease are provided.

Methods and compositions for treatment of a genetic condition

Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.

Methods and compositions for targeted cleavage and recombination

Disclosed herein are methods and compositions for modulating expression of a PD1 gene.

Methods and compositions for modulating PD1

Disclosed herein are methods and compositions for targeted modification of one or more endogenous plant malate dehydrogenase genes.

Targeted modification of malate dehydrogenase

The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.

Nuclease-mediated regulation of gene expression

Methods and compositions for modifying stem cells using one or more ZFPs are disclosed. Such methods and compositions are useful for facilitating processes such as, for example, dedifferentiating cells, differentiating stem cells into the desired phenotype, propagating stem cells and/or facilitating cloning.

Modulation of stem cells using zinc finger proteins

Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.

Methods and compositions for modification of a HLA locus

Disclosed herein are methods and compositions for targeted deletion of double-stranded DNA. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain, and polynucleotides encoding same. Methods for targeted deletion include introduction of such fusion proteins, or polynucleotides encoding same, into a cell such that two targeted cleavage events occur. Subsequent cellular repair mechanisms result in deletion of sequences between the two cleavage sites.

Targeted deletion of cellular DNA sequences

Disclosed herein are zinc fingers comprising CCHC zinc coordinating residues. Also described are zinc finger proteins and fusion proteins comprising these CCHC zinc fingers as well as polynucleotides encoding these proteins. Methods of using these proteins for gene editing and gene regulation are also described.

Optimized non-canonical zinc finger proteins

The present disclosure relates to engineered zinc finger proteins that target 5-enolpyruvyl shikimate-3-phosphate synthase (EPSPS) genes in plants and methods of using such zinc finger proteins in modulating gene expression, gene inactivation, and targeted gene modification. In particular, the disclosure pertains to zinc finger nucleases for targeted cleavage and alteration of EPSPS genes.

Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes

Disclosed herein are methods and compositions for targeted integration and/or targeted excision of one or more sequences into a cell, for example, for expression of one or more polypeptides of interest.

Targeted genomic alteration

Growing community of inventors

Richmond, CA, United States of America

Fyodor Urnov